PHARMAC's year in review leaves much to be desired


1 January 2023 - Christmas came early for a number of long-suffering patients.

PHARMAC’s advent calendar was opened with the bungled announcement that PHARMAC was consulting on the funding of Trikafta for cystic fibrosis patients in record time, after the application sat with PHARMAC for 1½ years.

That was followed by news that New Zealand would be the 66th country to fund Spinraza for spinal muscular atrophy, the 60th country to fund Keytruda for those with lung cancer, and the 62nd country to fund Stelara for Crohn’s and colitis.

Read Stuff article

Michael Wonder

Posted by:

Michael Wonder